Breakdown | ||||
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
875.56K | 1.72M | 3.42M | 6.58M | 5.01M | Gross Profit |
-2.08M | -3.08M | 498.15K | 2.66M | 1.14M | EBIT |
-4.96M | -7.45M | -5.89M | -4.11M | -3.67M | EBITDA |
-8.03M | -7.98M | -5.48M | -3.95M | -4.00M | Net Income Common Stockholders |
-6.41M | -7.95M | -5.41M | -4.23M | -4.82M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
434.40K | 2.03M | 3.67M | 8.05M | 6.39M | Total Assets |
2.31M | 3.50M | 5.31M | 10.35M | 8.91M | Total Debt |
1.83M | 963.13K | 0.00 | 0.00 | 0.00 | Net Debt |
1.40M | -1.07M | -3.67M | -8.05M | -6.39M | Total Liabilities |
7.63M | 4.21M | 1.85M | 1.69M | 4.11M | Stockholders Equity |
-5.32M | -703.36K | 3.47M | 8.66M | 4.81M |
Cash Flow | Free Cash Flow | |||
-928.17K | -5.83M | -4.38M | -5.86M | -3.68M | Operating Cash Flow |
-913.98K | -5.68M | -4.18M | -5.83M | -3.22M | Investing Cash Flow |
-1.94M | -289.61K | -207.44K | -26.87K | -463.58K | Financing Cash Flow |
764.83K | 4.14M | 0.00 | 7.50M | 7.23M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
46 Neutral | $3.31M | ― | -21.29% | ― | 80.87% | 82.44% | |
46 Neutral | AU$15.87M | ― | -64.72% | ― | 139.19% | 33.33% | |
39 Underperform | AU$4.26M | ― | ― | -49.04% | 32.85% | ||
39 Underperform | $9.33M | ― | -164.01% | ― | -18.80% | -46.65% | |
37 Underperform | AU$19.74M | ― | -218.38% | ― | -14.30% | 29.69% |
Bod Science Limited has announced a change in its registered office and principal place of business to a new address in Sydney, Australia. This move, approved by the Deed Administrator, reflects the company’s ongoing restructuring efforts under a Deed of Company Arrangement. The change is part of Bod’s strategic initiatives to strengthen its operational framework and potentially improve its market positioning.
Bod Science Limited has announced a change in its company secretary, with Carlie Hodges resigning and Joanne Patterson being appointed as her replacement. This change occurs as the company continues to operate under a Deed of Company Arrangement, reflecting ongoing restructuring efforts. The appointment of a new company secretary may impact the company’s administrative operations and stakeholder relations as it navigates its current financial and strategic challenges.
Bod Science Limited has entered into a Deed of Company Arrangement with Biortica Agrimed Limited, which includes a Share Purchase Agreement to acquire Biortica’s shares. The completion of this arrangement is contingent on meeting certain conditions, including shareholder approvals and compliance with ASX requirements. The company reported a net cash inflow from operating activities of $42k for Q3 FY2025, with customer receipts increasing significantly due to new product introductions. The arrangement and financial updates reflect Bod’s strategic efforts to stabilize and grow its operations amid ongoing corporate restructuring.
Bod Science Limited is undergoing a Deed of Company Arrangement (DOCA) with Biortica Agrimed Limited, which was executed in April 2024. The DOCA period has been extended to June 2025 due to delays in meeting ASX requirements, and an extraordinary general meeting will be scheduled once conditions are met.